The FCF Life Sciences Venture Capital Monitor – Europe is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies, displaying Venture capital financing trends in the European Life Sciences industry.
As of the end of August 2022 we identify the following current VC trends in Europe:
- In 2022, overall Life Sciences funding has reached EUR 6,501m so far
- Top 5 Deals exceed EUR 120m each, largest transaction amounted to EUR 500m in Doctolib (France)
- Bpifrance (France) dominates the Top 5 Investors (by deal volume), followed by Eurazeo (France) and General Atlantic (United States)
- Biotech received 43% of the total investment volume, (+1% compared to the previous month)
- Oncology still dominates as the top indication in Biotechnology
Capital Markets Research
We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:
Venture Capital
Licensing
Life Sciences Venture Capital Monitor – Europe
Monthly Venture capital activities in the European Life Sciences sector
Biotech Venture Capital Monitor – USAMonthly Venture capital activities in the US Life Sciences sector
Life Sciences Venture Capital ReportRecent Venture capital trends in the European Life Sciences sector
Other Research
Life Sciences IPO ReportRecent IPO trends in the Life Sciences sector
Biotech Public Equity MonitorRecent valuations of listed European Life Sciences companies
MedTech & Diagnostics Public Equity MonitorRecent valuations of listed MedTech companies
Life Sciences SPAC MonitorPerformance overview of merged Life Sciences SPACs
NEWS
US year-to-date funding volume now below previous year’s level
After an exceptional year 2021 for venture capital funding in the US Biotech-sector, aggregated financing volumes in 2022 are for the first time lower than in 2021. During the last months funding volumes have declined
FCF Biotech Venture Capital Monitor – USA 08/2022 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 08/2022”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
Overall negative Life Sciences Sentiments recorded in August 2022
The FCF Life Sciences team continuously analyses the current sentiments in the European life sciences venture capital funding sector. For August ’22, venture capital funding continues to decline. All life sciences subsectors (i.e. Biotech, HealthTech,
Life Sciences Venture Capital Monitor – Europe 08/2022 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 08/2022”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences
AgriTech sector on the rise with venture financing at record levels
Transaction volumes and the number of closed deals in the AgriTech space continued their steady growth in the US and massively surged in Europe. In the US, VC financing volumes in AgriTech more than doubled
